Because the safe use of the QTdrugs list of medications requires that the user have the most up-to-date version, we are informing you of the following changes:
The following drugs have been added to the Possible Risk (PR) of TdP category due to evidence that they are assicuated with QT prolongation when taken at clinically recommended doses.
Inotuzumab ozogamicin (Antibody-drug conjugate for leukemia)
Benperidol (neuroleptic, antipsychotic)
Due to emerging evidence of TdP under certain conditions, the antacid famotidine has been moved from the Possible Risk list to the Conditional Risk (CR) list (Conditions: renal failure, electrolyte disorder and concomitant use with QT/TdP drug).